Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

8-6-2021

The effects of developmental chlorpyrifos exposure on the
proteome of the adolescent rat hippocampus
Aubrey Lewis
Alewis522@gmail.com

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Lewis, Aubrey, "The effects of developmental chlorpyrifos exposure on the proteome of the adolescent rat
hippocampus" (2021). Theses and Dissertations. 5177.
https://scholarsjunction.msstate.edu/td/5177

This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Template C v4.3 (beta): Created by T. Robinson 01/2021

The effects of developmental chlorpyrifos exposure on the proteome of the adolescent rat
hippocampus
By
TITLE PAGE
Aubrey Lewis

Approved by:
Russell L. Carr (Major Professor)
Matthew K. Ross
George E. Howell, III
Larry A. Hanson (Graduate Coordinator)
David R. Smith (Dean, College of Veterinary Medicine)

A Thesis
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Master of Science
in Environmental Toxicology
in the College of the Veterinary Medicine
Mississippi State, Mississippi
August 2021

Copyright by
COPYRIGHT PAGE
Aubrey Lewis
2021

Name: Aubrey Lewis
ABSTRACT
Date of Degree: August 6, 2021
Institution: Mississippi State University
Major Field: Environmental Toxicology
Major Professor: Russell L. Carr
Title of Study: The effects of developmental chlorpyrifos exposure on the proteome of the
adolescent rat hippocampus
Pages in Study: 50
Candidate for Degree of Master of Science
Chlorpyrifos is a widely used organophosphate insecticide, functioning through the
inhibition of acetylcholinesterase. Recent studies report negative long-lasting biochemical and
behavioral effects at levels without acetylcholinesterase inhibition. Our lab studies have
identified the endocannabinoid system as a target for OP low-dose neurotoxicity. This thesis
identifies the proteins and their associated neurotransmitter systems in the hippocampus that
have been affected by low dose developmental exposure to the OP insecticide CPF. Male rat
pups were treated from postnatal day 10 (PND) – PND16 with either corn oil (vehicle), 0.75
mg/kg of CPF, or 0.02 mg/kg of PF-04457845, a specific fatty acid amide hydrolase (FAAH)
inhibitor. On PND38, rats were sacrificed for hippocampal extraction, and shotgun proteomics
was used for protein expression. DAVID and Ingenuity Pathway Analysis software detected
differentially expressed proteins such as Neuroligin-2 and Synaptotagmin 2, and disrupted
signaling pathways such as ephrin B signaling, synaptogenesis signaling, and glutamate receptor
signaling. Taken together, our data suggests that CPF reduces glutaminergic signaling pathways,
greatly reducing long-term potentiation, prohibiting proper synapse formation, and therefore
disrupting the proper functioning of the hippocampus.
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CHAPTER I
ORGANOPHOSHPHATES: AN INTRODUCTION TO THE HISOTYR AND USE, AND THE
CREATION OF CHLORPYRIFOS
1.1
1.1.1

Background
History of organophosphate compounds
The history of organophosphorus (OP) compounds dates back to the 1800s when

tetraethyl pyrophosphate was synthesized through the combination of alcohol and phosphoric
acid. When the cholinergic effects of OPs were discovered in the mid-1930s, the Nazi
government in Germany began creating OPs to serve as nerve agents (sarin, tabun), prior to
World War II. However, to date, the main use of nerve agents occurred during the Iran-Iraq war,
when the Iraqi army used tabun and sarin on the Iranian troops (Soltaninejad and Shadnia, 2014).
Today, OPs are common agents in fire retardants and are used as plasticizers for the creation of
plastics but the most common environmental use for organophosphates is as an insecticide.
Organophosphate insecticides became increasingly popular once insect resistance to the
organochlorine insecticides (dieldrin, aldrin, chlordane) occurred and increased even more
popular after those insecticides were banned. While the usage of organophosphorus insecticides
in the United States has been decreasing since the passage of the Food Quality Protection Act in
1996, they still account for approximately 33% of all insecticides used (Atwood and PaisleyJones, 2017). One of the main organophosphate pesticides still used today is chlorpyrifos (CPF)
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which is used in a multitude of different settings including on agricultural crops and golf turfs
and in greenhouses.
1.1.2

Chlorpyrifos
Chlorpyrifos (CPF) was registered by Dow Chemical Company in 1965 for use in the

control of foliage and soil-borne insect pests in food and crops (U.S. EPA, 2002). Since its
development, it has been one of the most popular choices for use considering its classification as
a broad-spectrum insecticide (Gurunathan et al. 1998). The structure of CPF contains a
pentavalent phosphorus atom, making a double bond with sulfur in its inactive state. Upon
bioactivation of CPF through cytochrome P450 monooxygenase, CPF is converted into its
bioactive “oxon” form, in which the phosphorus-sulfur moiety is changed to a phosphorusoxygen moiety. In this form, it exerts its neurotoxicity through the inhibition of
acetylcholinesterase (AChE), its canonical pathway. This allows the accumulation of
acetylcholine at places like nerve terminals, autonomic ganglia synapses, and neuromuscular
junctions, causing excessive stimulation of the cholinergic nicotinic and muscarinic receptors
(Forsyth et al. 1989; Buratti et al. 2002). Symptoms of high dose exposure from OP pesticides
are the traditional symptoms of over-cholinergic stimulation, which include sweating, wheezing,
muscle twitching, vomiting, convulsions, paralysis, respiratory arrest, and eventually death
(Zheng et al. 2000; Slotkin et al. 2004). However, developmental exposure to OP insecticides
that do not induce cholinergic signs of toxicity has been implicated in producing negative longlasting effects in laboratory animals such as reduced anxiety-like behavior (Moreira et al. 2008;
Chen et al. 2011a; Carr et al. 2017), anhedonia (Aldridge et al. 2005a), and depressive-like
behavior (Chen et al. 2014). In children, decreased cognitive abilities and motor skills and
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increased manifestation of attention-deficit/hyperactivity disorder have been associated with CPF
exposure (Engel et al. 2011; Rauh et al. 2006).
1.2
1.2.1

Literature Review
The effects of developmental OP exposure on the Endocannabinoid System
The developing nervous system in neonates and juveniles is much more susceptible to

damage compared to adults, providing a critical window for the disruption of neurogenesis,
synaptogenesis, and axonogenesis to occur if exposed to a toxicant, and thus can disrupt any
processes required for normal development (Slotkin et al. 2004). Moreover, some studies have
demonstrated altered neurochemical parameters and behavior following developmental exposure
to varying OP insecticides, all of which only occurred at levels that caused minimal inhibition of
AChE (Aldridge et al. 2004; Slotkin et al. 2006). These studies suggest that, at low levels, OP
insecticides function through a different, “non-cholinergic” pathway that remains unclear.

The adverse effects of developmental OP exposure have been studied in rats and the
effects have been observed in varying neurotransmitter systems such as serotonergic (Aldridge et
al. 2003; Aldridge et al. 2004; Aldridge et al 2005b, Aldridge et al. 2005c), dopaminergic system
(Aldridge 2005b, Chen et al. 2011b, Zhang et al. 2015), and the endocannabinoid system (Carr et
al. 2011, 2013, 2014; Nomura et al. 2008). Our laboratory has previously reported that following
repeated low dose CPF exposure (1mg/kg) of juvenile rats, there was greater inhibition of brain
fatty acid amide hydrolase (FAAH) than brain AChE (Carr et al. 2011). FAAH is an enzyme in
the endocannabinoid system. The endocannabinoid system is a neuromodulatory system that
participates in physiological processes such as mood, memory, appetite, pain-sensation, and
many others (Taber et al. 2009). It also plays a crucial role in the development of the nervous
3

system (Moreira et al. 2008; Harkany et al. 2007; Anavi-Goffer and Mulder 2009) and, therefore,
any disruption of the function of the endocannabinoid system during brain development could
lead to long-lasting negative effects. The two main endogenous endocannabinoids are 2arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide or AEA) (Stella et al.
1997) which are degraded by monoacylglycerol lipase (MAGL) and FAAH, respectively. AEA
and 2-AG both work in a retrograde fashion and bind to either cannabinoid (CB) receptors CB1
in the CNS, or CB2 receptors, located mainly in immune cells. Previous work in adults has
demonstrated that inhibition of the enzymes following exposure to high levels of OP insecticides
leads to accumulation of AEA and 2-AG (Quistad et al. 2001, 2002, 2006; Nomura et al. 2008;
Nomura and Casida 2011). Since the endocannabinoid system plays such an important role in
normal brain development, exposure to low levels of OPs during development could result in the
accumulation of the endocannabinoids which would inappropriately stimulate this signaling
pathway and lead to alterations in the development of necessary functioning neurotransmitter
systems. In support of this idea, some studies have previously reported that excessive activation
of the CB1 receptor by the inhibition of FAAH and accumulation of AEA in adolescents induces
long-term changes in the nervous system of the adults including behavioral changes (Marco et al.
2009; Macri et al. 2012). Thus, the endocannabinoid system is a possible target for neurotoxicity
during developmental low-dose exposure to OPs.

1.2.2

Chlorpyrifos and its effect on the hippocampus
One brain region to consider when talking about endocannabinoid function is the

hippocampus due to its high concentration of CB1 receptors, as well as its function in the limbic
system. It mainly functions in episodic and declarative memory but also functions in emotion
4

and exploratory and social behaviors. A major source of input/output for the hippocampus lies
within the entorhinal cortex (EC), which acts as the main interface between the hippocampus and
other brain regions. This feature allows information to flow unidirectionally, first with the
superficial layers of EC providing input. Once the information leaves the superficial layers of
the EC, it then flows into the hippocampus, first to the dentate gyrus (DG), next, to a cornu
ammonis (CA) CA3 layer (O’Keefe and Nadel 1978), then to the CA1 layer, and then, finally,
returns to the deepest layer of the EC for message output. Other areas of the brain that send
input to the hippocampus via the EC include the cingulate cortex, temporal lobe cortex,
amygdala, orbital cortex, and olfactory bulb (Neuroscience Online). CB1 receptors are found in
the dentate gyrus and superficial layers of the entorhinal cortex, and they mainly function on
GABAergic interneurons of these layers; however, it has been reported that CB1 receptors are
also found in glutamatergic cell bodies (Monory et al. 2006). The CA1-CA3 layers of the
hippocampus are comprised entirely of pyramidal cells, allowing them to respond to both
excitatory and inhibitory signals. This response capacity allows it to function in its main role,
synaptic plasticity and long-term potentiation (LTP). The process of LTP is what is required for
the creation of memories (Teyler and Discenna 1985) by constantly creating and strengthening
new synapses that allow for effective and fast cellular communication. There have been studies
reporting interference or blockage of the process of LTP due to the presence of exogenous
cannabinoids (Hampson et al. 1999) and excessive endogenous cannabinoids (Slanina et al.
2005). Children with exposure to OP insecticides have been associated with decreased working
memory and IQ (Rauh et al., 2011) possibly suggesting the disruption of memory formation.
This is accompanied by altered brain morphology (Rauh et al., 2012). Studies in animal models
using low and high doses of CPF have seen changes in working memory and spatial memory
5

(Levin et al. 2001; Chen et al. 2012). However, these studies are frequently conducted at levels
of CPF exposure that would exert cholinergic inhibition.

1.2.3

FAAH and its role in anxiety
The use of pharmacological agents such as URB597, a specific FAAH inhibitor,

has been reported to specifically increase the levels of the endogenous cannabinoid AEA in the
hippocampus thereby activating CB1 receptors. However, this did not cause long-term changes
to CB1 activation in other brain regions such as the amygdala or prefrontal cortex (Marco et al.
2009). AEA may play a larger role in the hippocampus than currently understood. The
hippocampus is one of the last regions of the brain to develop with neurogenesis and
synaptogenesis persisting well into adolescence (Slotkin et al. 2001). Therefore, disruption of the
development of the hippocampus can greatly change the “wiring” of the hippocampus. It could
be that accumulation of AEA decreases the rate of LTP, thus, reducing synaptic plasticity,
allowing for less synaptic communication, and ultimately leading to long-term signaling
dysfunction.

Developmental CPF exposure results in persistent effects on behavior. Several studies
have demonstrated altered behaviors associated with anxiety (Aldridge et al., 2005; Ricceri et al.,
2003, 2006) following developmental CPF exposure but the dosages used in these studies were
at levels that inhibited AChE. Our laboratory wanted to better understand how behavior might
be affected by developmental exposure to levels of CPF that do not inhibit AChE. By choosing
dosages that span the range between no brain AChE inhibition to minimal brain AChE inhibition
(0.5-1.0 mg/kg) (Carr et al. 2013, 2014), it allowed for a more accurate representation of the
6

neurochemical changes in different neurotransmitter systems with respect to adolescent behavior.
To better understand how minimal AChE inhibition affected behavior, rats were dosed (0.5-1.0
mg/kg) on PND10-16 and an emergence test was conducted on PND25. The developmental
exposure to CPF altered normal emergence behavior and reduced levels of anxiety as compared
to control rats (Carr et al. 2017). It is well documented that increasing AEA levels in the adult
brain, either by genetic deletion or pharmacological inhibition of FAAH activity, leads to
anxiolytic behavior in multiple tests of anxiety (Kathuria et al. 2003; Patel and Hillard, 2006;
Naidu et al. 2007; Moreira et al. 2008; Kinsey et al. 2011). It’s also been documented that low
doses of cannabinoid agonists, both endogenous or exogenous, can induce anxiolytic responses
whereas high doses promote anxiogenic responses (Moreira et al. 2008; Naidu et al. 2007).
However, these effects with the FAAH inhibitors were observed immediately following exposure
representing the effects of over-stimulation of the CB1 receptor at the point of behavior. In our
previous studies, the behavioral effects reported occurred at ~10 days following cessation of
exposure which does not directly correlate with the previous FAAH inhibition studies. In our
exposure paradigm, there would be increased activation of the CB1 receptors during the
exposure due to AEA accumulation but the behavioral changes that we observed were the longterm outcomes of that activation. Since hippocampal CB1 receptors have been known to be
involved in the modulation of fear and anxiety (Moreira et al. 2008), it’s reasonable to assume
altering the activation pattern of the receptors during juvenile ages could result in persistent
effects in that region. There may be a connection between persistently altered hippocampal
function and dysregulation of anxiolytic behavior.
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To better understand the role of FAAH inhibition on behavior, Carr et al. (2017) treated
rat pups from PND10-16 with either corn oil (vehicle), low CPF (0.5 mg/kg), medium CPF (0.75
mg/kg), high CPF (1.0 mg/kg), or PF-04457845 (0.02 mg/kg), a specific FAAH inhibitor. Once
adolescence was reached, the rats were tested in several behavioral tests including the open field
test (PND23), the elevated plus maze (EPM) (PND29), and in a social behavior test (PND35-36).
All tests were conducted under high illumination (~600-700lux) to make it more stressful and
aversive. In all four treatment groups, rats exhibited reduced anxiety-like behavior possibly
bordering on anxiolytic behavior due to the amount of time spent in open arms during EPM and
increased social behavior. Other studies have also reported anxiolytic responses in the elevated
plus maze and altered social behavior following postnatal exposure to CPF (Aldridge et al.,
2005; Venerosi et al., 2006; Zanettini et al. 2011). It is known that the endocannabinoid system
plays a role in anxiolytic behavior. The CB1 receptors are located presynaptically on both
glutamatergic pyramidal cells and GABAergic interneurons with higher levels of these receptors
on interneurons as compared to pyramidal cells. This allows control of inhibitory and excitatory
neurotransmission. This endocannabinoid presynaptic function also allows for opposing effects
to occur in brain systems that are known for anxiety response. An example of a brain region
where this could take place is the hippocampus, given its high concentration of CB1 receptors
(Moreira et al. 2008). However, the exact role of CB1 receptors in the hippocampus on anxiety
is still unknown. In a review by Zanettini et al. (2011), there is contradicting evidence on the
effects of endocannabinoids in emotional behavior. Zanettini suggested discrepancies between
CB1 receptor activity and behavioral effects exist and could be due to differences in the
expression of CB1 receptors, the location and quantity of inactivation, and the functional
characteristics of the receptor. These discrepancies argue for more research on the hippocampus
8

(Moreira et al. 2008; Chen et al. 2014) with respect to OP exposure since OP insecticides greatly
interfere with different neurotransmitter systems (i.e. serotonin, dopamine) that are heavily
prominent in the hippocampus. Filling this gap of critical knowledge is crucial so we can
understand how to overcome OP poisoning. In a review on the function of the hippocampus
concerning social behavior, Rubin et al. (2014) argued that the hippocampus is more involved in
social behavior and anxiety-regulation than previously thought. He also added that hippocampal
dysfunction can lead to anxiety and a list of other disorders. Ultimately, the specific
involvement of the hippocampus regarding social behavior requires more research.

The amygdala, another structure of the limbic system, is also involved in mood and
emotionality and works with the hippocampus for memory consolidation (Vatanparast et al.
2013). Therefore, it can be expected that a change in signaling in the amygdala could result in a
change of signaling in the hippocampus. Our lab wanted to better understand the role of anxiety
in CPF neurotoxicity. Upon concluding behavioral testing (EPM, social play), a genomics
analysis suggested that there was a large imbalance in GABA/glutamate signaling, favoring
larger GABA concentrations. The neurotransmitter imbalance favoring inhibitory rather than
excitatory corresponds with the anxiolytic behavior exhibited by our rats exposed
developmentally to CPF. This imbalance may function to reduce LTP in the amygdala, reducing
the abilities of emotional memory (Suvrathan et al. 2014), and thereby affecting behavior. The
process of LTP begins through the release of glutamate into the synapse, acting on glutamate
receptors, and increasing the Ca2+ concentration into the postsynaptic neuron. The increase in
Ca2+ allows for the phosphorylation of AMPA receptors, increasing glutamate signaling (Lisman
et al. 2012). Therefore, increased GABAergic activity would lead to a decrease in glutamate
9

concentration which would affect LTP and proper amygdala function, potentially causing the
effects in the hippocampus.

1.2.4

Developmental OP exposure in children
The effects of CPF in rats have been observed in humans, specifically in children.

As previously stated, since the nervous system is so susceptible to damage in newborns and
juveniles, exposure to foreign substances can cause more harm than that of an adult. While the
residential use of CPF was restricted in 2000 by the EPA, it was still detected in 78% of the
homes surveyed in the US (Burke et al. 2017). In addition, it is still used in agriculture and in
commercial settings and, thus, still poses a threat to children. CPF exposure in pregnant women
poses a threat to the fetus, as prenatal exposure for OPs has been noted to cause babies to have
lower weight and size, smaller head circumference, impaired cognitive function, higher
incidence of ADHD, and deficits in working and reference memory (Burke et al. 2017).
Furthermore, there have been emerging studies analyzing the concentration of OPs inside
daycares and preschools (Morgan M. et al. 2005). Accordingly, individuals spend 90% of their
time indoors (Gurunathan et al. 1998) and studies agree that the main exposure to insecticides
occurs indoors (Kim et al. 2013; Morgan et al. 2005; Gurunathan et al. 1998). However, some
argue the main method of exposure is inhalation (Kim et al. 2013) while others consider it to be
dietary (Morgan et al. 2005). It is possible that combined exposure via multiple routes could
help explain why developmental exposure to OP insecticides has been suggested to have longlasting negative impacts. Currently, there are not studies relating the dose of CPF exposure in
juveniles and toxicity. Therefore, this research aims to help identify a dose that could potentially
relate to daily exposure levels and toxicity.
10

1.3

Rational of research
The causes of reduced anxiety-like behavior and altered social behavior resulting from

low-dose developmental OP insecticide exposure remain unclear. Our previous work has
focused on the effects of juvenile CPF exposure on the proteome and genome of the amygdala of
adolescent rats. The present study will further that work by focusing on the hippocampus and
will determine the effect of juvenile CPF exposure on the proteome. This will allow us to
determine changes in the differentially expressed proteins in the hippocampus that may
contribute to anxiolytic behavior. It will also allow us to determine the neurotransmitter systems
affected in the hippocampus. It is our hope that this proteomics analysis will allow us to identify
a connection between the changes in the expression of proteins and the changes in behavior
observed during our social play experiments. We also expect to identify the proteins that are
altered due to inhibition of FAAH by comparing the control group with the PF-04457845
treatment group. Further, we will compare the changes in the CPF treatment group with the
changes in the PF-04457845 treatment group to determine any similarities in protein expression
between these two treatment groups. Similar changes in protein expression between these groups
would be indicative of the involvement of disruption in endocannabinoid signaling as the
causative factor. Once we understand the proteins present and their associated neurotransmitter
systems, it will allow us to better understand how CPF alters hippocampal function resulting in
disrupted behavior. This will get us one step closer to understanding the impact of low-dose
developmental CPF exposure. Our hypothesis for this experiment is juvenile OP exposure to
CPF alters synaptic components/connections of the hippocampus that are important in normal
emotional behavior.
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CHAPTER II
MATERIALS, METHODS, AND PROCEDURES
2.1
2.1.1

Materials
Animal Treatment
Adult male and female Sprague Dawley rats were used for breeding. These rats were

housed in an American Association for Accreditation of Laboratory Animal Care (AAALAC)
accredited facility under constant temperature (22˚C), on a 12 h light and 12 h dark cycle with
lights on between 0700 and 1900. Rats were provided with food and water ad lib. Males and
females were placed together for breeding and females were separated from males once visibly
pregnant. The date of birth was designated as PND0. Rat pups within each litter were assigned to
different treatments and the pups were marked for identification. Male Sprague Dawley rats were
treated daily by oral gavage from PND10-16 as previously described (Carr et al. 2011; Carr et al.
2013; Carr et al. 2014). There were three treatment groups with three animals in each group: 1)
corn oil (control); 2) 0.75 mg/kg CPF; and 3) 0.02 mg/kg PF-04457845 (a specific inhibitor of
FAAH). PF-04457845 was used as a positive control because it is a very selective FAAH
inhibitor and has been reported to be effective when administered orally (Ahn et al. 2011).
Treatment occurred at a volume of 0.5 ml/kg and body weights were recorded during the
treatment period. Rats were weaned on PND21 and marking continued until sacrifice to allow
identification. Rats were sacrificed on PND38, and brains were collected and stored at -80˚C.
Frozen brains were sliced using a manual tissue slicer to obtain 500-micron sections which were
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stored on microscopic slides until the hippocampus was collected by dissection using a
sharpened scalpel. The Paxinos and Watson (1998) atlas was used as a reference. The tissue was
then collected in lysis buffer and stored at -80˚C until sample preparation.
2.2
2.2.1

Methods
Sample preparation for proteomic analysis
Collected tissue was lysed in NP-40 lysis buffer (150 mM NaCl, 20 mM MgCl2, 50 mM

Tris-HCl pH 7.4, 0.5% NP-40) supplemented with 1 mM of the serine protease inhibitor,
phenylmethylsulfonyl fluoride (PMSF) using a MicrosonTM ultrasonic cell disruptor. The debris
was removed by centrifugation at 21,000g at 4˚C for 30 min. The protein concentration was
measured using a PierceTM BCA protein assay kit (Thermo Scientific). From each sample, 100
µg of protein was precipitated by chloroform/methanol extraction. Briefly, sample volume was
adjusted to 200 µl using NP-40 lysis buffer. To each sample, 600 µl of methanol, 150 µl of
chloroform, and 450 µl of milliQ-H2O were added, vortexed, and centrifuged at room
temperature for 1 min, at 21,000g. The upper aqueous phase was discarded and 450 µl of
methanol was added to the lower phase, vortexed, and centrifuged under the same conditions for
2 min. The supernatant was discarded and protein digestion was performed by suspending the
pellet in 33 µl of 100 mM Tris-HCl (pH 7.8) containing 6 M urea. The samples were reduced
with 1.6 µl of 200 mM dithiothreitol (DTT) for 45 min at room temperature and alkylated with
6.6 µl of 200 mM iodoacetamide (IAA) for 45 min at room temperature. The alkylation reaction
was quenched by adding 20 µl of 200 mM DTT for 45 min at room temperature. The urea
concentration was reduced by adding 258 µl of milliQ-H2O. Finally, the proteins were digested
with trypsin (sequencing grade modified trypsin, Promega) at a 1:50 ratio for 18 hr at 37˚C.
Protein digestion was terminated by lowering the pH of each sample to <6 by adding
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concentrated acetic acid. The samples were desalted using C18 SepPak columns (Waters, USA).
The samples were then dried down in a speed vac. The resulting dried peptide samples were
dissolved in Milli-Q-H2O containing 2% acetonitrile and 0.1% formic acid. All samples were
submitted to the University of California – Davis Proteomics Core Facility for analysis using a
Q-exactive+ mass spectrometer with a Proxeon nano-spray source and Easy-LC II HPLC.
2.3
2.3.1

Procedures
Data Analysis
Post identification processing, protein grouping, and validation of protein identification

were done by using Scaffold (version Scaffold_4.5.1, Proteome Software Inc., Portland, OR). A
reverse decoy database strategy was used to check the false discovery rate for peptides and
proteins. Protein identifications were accepted if they could be established at greater than 95.0%
probability and contained at least 2 identified peptides by the Scaffold Local FDR algorithm.
Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al. 2003).
Proteins that contained similar peptides and couldn’t be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide
evidence were grouped into clusters. Label-free protein quantitation using the sum of weighted
spectra associated with a protein was performed in Scaffold. The proteins that passed the
Fisher’s exact test with a p-value of ≤ 0.07 were used for biological interpretation. Differentially
expressed proteins were identified based on their fold change which was then calculated by
applying normalization in Scaffold.
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2.3.2

Gene ontology and network analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used

for functional annotation (https://david.ncifcrf.gov/home.jsp) (Dennis et al., 2003). The gene
name for each differentially expressed protein was submitted to DAVID. Statistical significance
of the enriched GO terms was determined by an EASE Score Threshold (a modified Fisher Exact
p-value) of 0.07. The significant GO terms for biological processes, molecular function, and
cellular components were determined.
Bioinformatics analysis was performed using Ingenuity Pathway Analysis (IPA,
QIAGEN Inc., Valencia, CA; https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). The protein name, p-value, and fold change for each differentially expressed
protein were submitted to IPA for functional annotation to identify the canonical pathways and
molecular/cellular and physiological functions that were significantly affected by the treatments.
The main focus was to identify the pathways that are associated with endocannabinoid,
opioid, serotonergic, and dopaminergic systems. However, other networks that are associated
with differentially expressed proteins such as cell-cell signaling and interactions, nervous system
development and function, and cellular assembly and organization have also been identified

2.3.3

Western Blots
Western Blots were used to confirm protein significance patterns between groups. The

protein concentration of samples was determined through the use of Thermo Scientific PierceTM
BCA Assay Kit Lot: UH289344 according to company protocol. Samples were prepared with
30μg of protein, 6x SDS-loading buffer, and RIPA buffer. All samples were heated at 95C for 5
minutes. 24 μL of the sample was added to each lane, and 3 μL of a molecular marker was used
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in the last lane of a 10% polyacrylamide gel. 10x Running Buffer was used to run the gels using
the Bio-Rad PowerPac Universal system. Gels were run at constant V at 100V for 15 minutes,
then constant V at 120V for 1 hour. Gels were transferred using Bio-Rad Tray-blot SD Semidry
Transfer Cell containing transfer buffer for a constant V at 20V for 30 minutes. Transfer
membranes were blocked in 5% milk Tris-Buffered Saline-Tween Buffer (TTB) for 2 hours at
room temperature. Antibodies from Santa Cruz Biotechnology (Dallas, TX) at varying dilutions
were used as primary antibodies: Na+/K+-ATPase α (H-3): sc-48345 at 1:1000, VDAC (B-6):
sc-390996 at 1:100, and EAAT2 (E-1):sc-365634 at 1:200, and m-IgG BP-HRP (sc-516102-CM)
at 1:5000 dilution was used at secondary antibody. Primary antibodies were incubated for 2
hours at room temperature or overnight at 4°C and secondary antibody was incubated at room
temperature for 90 minutes. Membranes were washed between each antibody in TTB buffer for 5
minutes, three times. Membranes were incubated with SuperSignal (Thermo Scientific West
Pico PLUS Chemiluminescent Substrate Cat: 34580) for the detection of bands. All membranes
were imaged using the Bio-Rad ChemiDoc MP system at the setting of chemiluminescence. βActin was used as a positive control for sample concentration verification. Quantification of
blots was completed through the use of Bio-Rad Image Lab software for Mac (SOFT-LIT-1709690—ILMAC-V-6-1).
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CHAPTER III
RESULTS
3.1

A comparison of detected proteins between treatment groups
For the analysis, the number of proteins was similar for each treatment group (2,708 for

control, 2,738 for CPF, and 2,708 for PF). A breakdown of the distribution of detected proteins
for each treatment group is presented as a Venn diagram in Figure 3.1. Scaffold allowed us to
determine the spectral count for each protein and the significance between treatments. When
comparing the control group to treated groups, CPF had 273 differentially expressed proteins,
and PF had 298 differentially expressed proteins compared to control. Of these, only 92 were
present in both comparison groups (Figure 3.2). The main “group” of proteins changed by
treatment were housekeeping genes, such as ones that control actin and the cytoskeleton. The
control group had a higher protein count, on average, compared to CPF or PF. To measure this,
spectral counts were provided in Scaffold, assigning a numeric value to each protein regarding
the amount present in each sample. When comparing control groups to the treatment groups,
control had a slightly higher spectral count than both CPF (Figure 3.3A) and PF (Figure 3.3B).
The purpose of this step was just to visualize how protein concentrations were affected through
treatment. The control groups vary slightly on count because the CPF treatment group had more
proteins identified compared to the PF group.
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Figure 3.1

A breakdown of the distribution of the detected proteins for each treatment group
(2,708 total proteins in control, 2,738 total proteins in chlorpyrifos (CPF), and
2,708 total proteins in PF-04457845 (PF)).

Figure 3.2

A breakdown of the distribution of the significantly altered proteins for each
control vs chlorpyrifos (CPF) (273 proteins) and control vs PF_04457845 (PF)
(298 proteins)
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Figure 3.3

Average of the spectral counts between (A) control and chlorpyrifos (CPF) and (B)
control and PF-04457845 (PF). Spectral counts are defined as the number of
proteins present for that protein of name. The number was calculated by adding up
all the significant protein’s quantity, then dividing the sum.

Green – control; Red – CPF; Blue – PF

3.2

Gene Ontology analysis
Using the DAVID gene ontology tool, 262 of 267 differentially expressed proteins were

mapped for the Control vs CPF analysis and 283 of 292 differently expressed proteins were
mapped for the Control vs PF analysis. Using the DAVID functional annotation tool, the altered
biological processes, cellular components, and molecular functions were identified. Based on the
count of the proteins involved, many of the top biological processes altered for CPF were also
altered for PF (Table 3.1). These included: positive regulation of GTPase activity, protein
phosphorylation, protein transport, neuron projection development, cytoskeleton organization,
regulation of Rho protein signal transduction, and regulation of membrane potential. Of these,
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neuron projection development and regulation of membrane potential are related to neurological
function. However, other biological processes related to neurological function that were
identified as altered for CPF but not PF included: neuron migration, regulation of postsynaptic
membrane potential, and positive regulation of dendrite extension. Additional biological
processes related to neurological function that were identified as altered for PF but not CPF
included: vesicle-mediated transport, axonogenesis, and neuronal action potential.

For the cellular components, the components related to neurological function were
identified for both CPF and PF (Table 3.2). For the 13 altered cellular components altered by
CPF, 10 of these were also altered for PF. These included: neuronal cell body, axon, dendrite,
cell junction, neuron projection, synapse, myelin sheath, postsynaptic density, growth cone, and
postsynaptic membrane. Three additional cellular components related to neurological function
(dendritic spine, vesicle, and dendritic shaft) were altered for CPF but not PF and one additional
cellular component related to neurological function (axon terminus) was altered for PF but not
CPF.

Based on the count of the proteins involved, the top molecular functions altered for CPF
were also altered for PF (Table 3.3). These included: protein binding, ATP binding, poly(A)
RNA binding, protein complex binding, and nucleotide binding. Two additional molecular
functions involved in neurological function, GTPase activator activity, and signal transducer,
were altered for both CPF and PF. Two other molecular functions involved in neurological
function (voltage-gated potassium channel activity and voltage-gated sodium channel activity)
were altered for CPF but not for PF.
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Table 3.1

Altered Biological Processes Identified by DAVID in Adolescent Rat
Hippocampus Alter by Juvenile Exposure to either Chlorpyrifos (CPF) or PF04457845 (PF)
Controls vs CPF

GO
Term‡
GO:
0043547
GO:
0006468
GO:
0015031
GO:
0031175
GO:
007010
GO:
0035023

GO:
0042391
GO:
001764

GO:
0060078

GO:
1903861

Description
of term
Positive
regulation of
GTPase
activity
Protein
phosphorylat
ion
Protein
transport
Neuron
projection
development
Cytoskeleton
organization
Regulation
of Rho
protein
signal
transduction
Regulation
of membrane
potential
Neuron
migration
Regulation
of
postsynaptic
membrane
potential
Positive
regulation of
dendrite
extension

Control vs PF

Count

%

p-value

GO
Term‡

19

7.25

<0.0001

GO:
0043547

14

5.34

0.0215

GO:
0006468

12

4.58

0.0009

GO:
0015031

8

3.05

0.002

GO:
0031175

8

3.05

0.002

GO:
0007010

Description
of term
Positive
regulation of
GTPase
activity
Protein
phosphorylati
on
Protein
transport
Neuron
projection
development
Cytoskeleton
organization
Regulation of
Rho protein
signal
transduction

Count

%

p-value

18

6.36

<0.0001

17

6.01

0.0032

12

4.24

0.0015

8

2.83

0.006

7

2.47

0.0117

9

3.18

<0.0001

7

2.47

0.003

9

3.18

<0.0001

8

3.05

0.0001

GO:
0035023

7

2.67

0.002

GO:
0042391

6

2.29

0.0284

GO:
0016192

3

1.15

0.0459

GO:
0007409

Axonogenesis

6

2.12

0.0294

3

1.15

0.0276

GO:
0019228

Neuronal
action
potential

4

1.41

0.0146

‡Gene Ontology

Regulation of
membrane
potential
Vesiclemediated
transport

Term (GO Term); Description of GO Term; Number of significant proteins
involved in term (count); Percentage of total significant proteins involved in the term (5); and
Statistical significance (p-value).
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Table 3.2

GO
Term‡
GO:
0043025
GO:
0030424
GO:
0030425
GO:
0030054
GO:
0043005
GO:
0045202
GO:
0043209
GO:
0014069
GO:
0030426
GO:
0045211
GO:
0043197
GO:
0031982
GO:
0043198

Altered Cellular Components Identified by DAVID in Adolescent Rat
Hippocampus Altered by Juvenile Exposure to either Chlorpyrifos (CPF) or PF04457845 (PF)
Control vs CPF
Description Count
of Term
Neuronal
24
cell body
Axon
20

%

p-value

9.16

0.0000

7.63

0.0000

Dendrite

16

6.11

0.0022

Cell junction

15

5.73

0.0013

Neuron
projection
Synapse

15

5.73

0.0009

12

4.58

0.0021

Myelin
sheath
Postsynaptic
membrane
Growth cone

11

4.19

0.0003

10

3.82

0.0049

8

3.05

0.0038

Postsynaptic
membrane
Dendritic
spine
Vesicle

7

2.67

0.0492

7

2.67

0.0148

7

2.67

0.0213

Dendritic
shaft

6

2.29

0.0012

GO
Term‡
GO:0043
025
GO:
0030424
GO:
0030425
GO:
0030054
GO:
0043005
GO:
0045202
GO:
0043209
GO:
0014069
GO:
0030426
GO:
0045211
GO:
0043679

‡Gene Ontology

Control vs PF
Description Count
of Term
Neuronal
24
cell body
Axon
13

%

p-value

8.48

0.0000

4.59

0.0067

Dendrite

15

5.30

0.0110

Cell junction

17

6.01

0.0003

Neuron
projection
Synapse

18

6.36

0.0001

14

4.95

0.0004

Myelin
sheath
Postsynaptic
density
Growth cone

13

4.59

0.0000

9

3.18

0.0234

8

2.83

0.0059

Postsynaptic
membrane
Axon
terminus

8

2.83

0.0254

5

1.77

0.0422

Term (GO Term); Description of GO Term; Number of significant proteins
involved in term (Count); Percentage of total significant proteins involved in term (%); and
Statistical significance (p-value).
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Table 3.3

Altered Molecular Function Identified by DAVID in Adolescent Rat Hippocampus
Altered by Juvenile Exposure to either Chlorpyrifos (CPF) or PF-04457845 (PF)
Control vs CPF

GO
Term‡
GO:
0005515
GO:
0005524
GO:
0044822
GO:
0032403
GO:
0000166
GO:
0005096
GO:
0004871
GO:
0005249

GO:
0005248

Description
of Term
Protein
binding
ATP
binding
Poly(A)
RNA
binding
Protein
complex
binding
Nucleotide
binding
GTPase
activator
activity
Signal
transducer
activity
Voltagegated
potassium
channel
activity
Voltagegated
sodium
channel
activity

Control vs PF

Count

%

p-value

GO
Term‡
GO:
0005515
GO:
0005524
GO:
0044822

58

22.14

<0.0001

39

14.89

0.0001

36

13.74

<0.0001

17

6.49

0.0001

GO:
0032403

14

5.34

0.0008

10

3.82

0.0032

GO:
0000166
GO:
0005096

7

2.67

0.0229

4

1.53

0.0429

3

1.15

0.0331

GO:
0004871

Description
of Term
Protein
binding
ATP
binding
Poly(A)
RNA
binding
Protein
complex
binding
Nucleotide
binding
GTPase
activator
activity
Signal
transducer
activity

Count

%

p-value

65

22.97

<0.0001

48

16.96

<0.0001

40

14.12

<0.0001

20

7.07

<0.0001

12

4.24

0/.0113

10

3.53

0.0048

12

4.24

<0.0001

‡Gene Ontology

Term (GO Term); Description of GO Term; Number of significant proteins
involved in term (Count); Percentage of total significant proteins involved in term (%); and
Statistical significance (p-value).
3.3
3.3.1

Bioinformatics: The use of Ingenuity Pathway Analysis (IPA)
Canonical pathway identification relating to neurological function
Ingenuity Pathway Analysis (IPA) allowed us to compile a list of the top canonical

pathways affected by CPF and PF treatment. For CPF, IPA identified 134 altered pathways for
CPF and 102 altered pathways for PF. Of these, the canonical pathways related to neurological
function that were altered by CPF and by PF are presented in Figure 3.7 and Figure 3.8,
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respectively. Nine pathways were identified as altered in both CPF and PF. These included (1)
ephrin B signaling, (2) synaptogenesis signaling pathway, (3) axonal guidance signaling, (4)
reelin signaling in neurons, (5) cholecystokinin/gastrin-mediated signaling, (6) ephrin receptor
signaling, (7) regulation of actin-based motility by rho, (8) semaphorin signaling in neurons, and
(9) glutamate receptor signaling. With respect to IPA’s predictions of inhibition or activation of
the pathway, the only agreement between CPF and PF was the prediction of activation of the
synaptogenesis signaling pathway. In most cases, IPA made a prediction made with one
treatment or was unable to make it with the other treatment. In contrast, the pathways ephrin
receptor signaling and regulation of actin-based motility by rho had opposite predictions with
both being activated with CPF but inhibited with PF. Interestingly, several of the proteins used to
make these predictions in one treatment were not used to make predictions in the other treatment
for the same canonical pathway even though they were significantly different in both data sets.
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Figure 3.4

Ingenuity Pathway Analysis (IPA) identified canonical pathways represented by
altered protein expression in hippocampus of adolescent animals treated with
0.75mg/kg chlorpyrifos. The blue color indicates the inhibition of pathway, orange
color indicates the activation of pathway, and white color indicates that there is no
activation/ inhibition of the pathway. Gray color means IPA cannot predict about
the activation state of that pathway. The color coding was given based on Z-score.
Threshold line indicates the p-value of 0.07 or -log (P-value) of 1.155. Ratio which
is represented in orange solid line refers to the number of molecules from the
dataset that map to the pathway listed divided by the total number of molecules
that define the canonical pathway from within the IPA knowledgebase
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Figure 3.5

Ingenuity Pathway Analysis (IPA) identified canonical pathways represented by
altered protein expression in hippocampus of adolescent animals treated with
0.02mg/kg PF-04457845. The orange color indicates the activation of pathway
and the white color indicates that there is no activation/inhibition of the pathway.
A grey color indicates IPA cannot predict about the activation state of the pathway.
The color coding was given based on Z-score. Threshold line indicates the p-value
of 0.07 or -log (P-value) of 1.155. Ration which is represented in orange solid line
refers to the number of molecules that define the canonical pathway from within
the IPA knowledgebase.
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There were also several canonical pathways related to neurological function that were
significantly altered with the CPF treatment that were not altered with the PF treatment. These
included GDNF family ligand-receptor interactions, endocannabinoid developing neuron
pathway, ephrin A signaling, and ERK/MAPK signaling. In a similar fashion, there were several
canonical pathways related to neurological function that were significantly altered with the PF
treatment that were not altered with the CPF treatment. These included Gαq signaling, αadrenergic signaling, CREB signaling in neurons, and Gαi signaling
3.3.2

Identification of top disease and functions

We next wanted to examine the top diseases & functions among treatment groups. The main
categories we identified as significant in regards to hippocampal/neurological function were:
1. Behavior
2. Neurological Disease
3. Nervous System Development and Function
In the Behavior category (Table 3.4), there were no similar annotations listed between CPF and
PF but no function received a sufficient z-score (>2.0 or <2.0) for IPA to predict whether the
function was increased or decreased. In the Neurological Disease category, there were 48
functions for CPF and 78 functions for PF that were identified as potentially significantly altered.
More functions in the PF treatment received a z-score but no predictions of increase or decrease
were made for any of those. For CPF, fewer functions were received a z-score but IPA predicted
that functions related to motor/movement disorders would be decreased with the CPF treatment.
No predictions were made for the Movement disorders in the PF treatment but it received a
negative z-score suggesting a decrease in that treatment as well.
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In the Nervous System Development and Function category, there were 52 functions for
CPF and 50 functions for PF that were identified as potentially significantly altered. Those
functions receiving a z-score for both treatment groups are presented in Table 3.5 and the results
were similar between the two groups. IPA predicted that Proliferation of neuronal cells, Growth
of neurites, Quantity of neurons, Extension of neurites and Growth of axons would be increased
in the CPF treatment. For the PF treatment, IPA predicted that Extension of neurites and Growth
of neurites would also be increased. The Proliferation of neuronal cells and Quantity of neurons
were not predicted to be increased in the PF treatment but both received a z-score very close to
2.0. However, Growth of axons was not identified as potentially significantly altered.
Interestingly, the migration of neurons was also predicted to be increased in the PF treatment but
was not even identified as potentially significantly altered in the CPF treatment. The majority of
these functions are related to neuronal cell connections.
Table 3.4

Diseases or Functions Annotations for Behavior
Control vs CPF

Function‡

p-value

Learning
Spatial learning

0.0121
0.0003

Activation
z-score
0.762
ND

Control vs PF
#
molecules
9
7

Function‡

p-value

Activation
z-score
-0.179
0.689

#
molecules
10
4

Locomotion
0.0008
Exploratory
0.0041
behavior
Thigmotaxis
0.0017
ND
3
Stereotypy
0.0012
ND
3
Hyperlocomotion
0.0024
ND
2
Vocalization
0.0042
ND
3
Autistic-like
0.0113
ND
1
Disinhibited
0.0058
ND
1
traits
behavior
‡Function identified as altered by the treatment; Statistical significance (p-value); Activation z-score indicates a
prediction of the direction that the function was altered such as activation (positive value), inhibition (negative
value), or no clear directionality (Not Determined or ND). An activation z-score is considered significantly activated
or inhibited when the z-score is greater than of less than -2 respectively; Number of significant proteins involved in
that function (#).
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Table 3.5

Diseases of Functions Annotations for Nervous System Function
Control vs CPF

Function‡

p-value

Proliferation of
neuronal cells
Growth of
neurites
Quantity of
neurons
Extension of
neurites
Growth of
axons
Growth of
dendrites
Development
of neurons
Outgrowth of
neurites
Morphogenesis
of neurons
Neuritogenesis
Axonogenesis

Quantity of
neurites
Branching of
neurites
Long-term
potentiation of
hippocampus

Control vs PF

<0.0001

Activation
z-score
2.936*

#
molecules
18

<0.0001

2.795*

17

0.0103

2.426*

9

0.0086

2.236*

5

0.0001

2.219*

8

0.0013

1.987

4

<0.0001

1.971

23

0.0001

1.886

12

<0.0001

1.782

19

<0.0001
0.0026

1.782
1.191

18
7

0.0036

1.067

4

0.0046

1.016

8

0.0001

0.579

6

Function‡

p-value

Extension of
neurites
Migration of
neurons
Growth of
neurites
Proliferation
of neuronal
cells
Quantity of
neurons
Outgrowth of
neurites
Quantity of
neurites
Development
of neurons
Axonogenesis
Neuritogenesis
Long-term
potentiation of
hippocampus
Branching of
neurites
Cell viability
of neurons

‡Function

<0.0001

Activation
z-score
2.575*

#
molecules
8

0.0032

2.226*

7

0.0005

2.129*

12

0.0007

1.917

13

0.0011

1.770

11

0.0012

1.720

10

0.0004

1.131

5

0.0011

0.732

17

0.0001

0.463

9

0.0001
0.0013

0.287
0.200

16
5

0.0003

-0.268

10

0.0024

-0.600

7

identified as altered by the treatment; Statistical significance (p-value); Activation zscore indicates a prediction of the direction that the function was altered such as activation
(positive value), inhibition (negative value). An activation z-score is considered significantly
activated or inhibited when the z-score is greater than 2 or less than -2, respectively; Number of
significant proteins involved in that function (#).
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Table 3.6

Diseases of Functions Annotations for Neurological Diseases
Control vs CPF

Function

p-value

Motor
dysfunction of
movement
disorder
Movement
disorders
Tremor
Seizure
disorder
Demyelination

Control vs PF
#
molecules
20

Function

p-value

0.0023

Activation
z-score
-2.63*

<0.0001

Activation
z-score
-1.57

#
molecules
20

Seizure disorder

0.0044

-2.433*

19

Seizures

<0.0001

-1.57

18

0.0039

-2

5

0.0010

-1.349

21

10

Movement
disorders
Gliosis

0.0141

-1.432

0.0006

-1.292

6

0.0111

-0.849

4

Memory deficits

0.0001

-1.264

6

Neurological signs

0.0011

-1.264

15

Astrocytosis

0.0004

-1.109

5

Degeneration of
neurons
Neurodegeneration

0.0031

-0883

7

0.0050

-0.608

8

Degeneration of
nervous system
Neurodegeneration
of neurites
Neurodegeneration
of axons

0.0025

-0.568

8

<0.0001

-0.276

6

0.0003

0.049

5

‡Function

identified as altered by the treatment; Statistical significance (p-value); Activation zscore indicates a prediction of the direction that the function was altered such as activation
(positive value), inhibition (negative value). An activation z-score is considered significantly
activated or inhibited when the z-score is greater than 2 or less than -2, respectively; Number of
significant proteins involved in that function (#).
3.4

Western Blotting
Lastly, we used the process of Western Blots to confirm our proteomics results. Initially,

we attempted to use several proteins of interest that were significantly altered including vesicular
glutamate transporter 2 (VGLUT2) and Ephrin receptor B1 (EphB1). However, the antibodies
did not detect any proteins probably due to the protein concentrations being below the detection
threshold. We then verified that our procedure was sufficient to detect proteins that were present
in our samples using antibodies present in the laboratory including protein kinase C, beta
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(PKCB1), calcium/calmodulin-dependent protein kinase II alpha (CaMKIIa), and myelin basic
protein (MBP). These antibodies worked well but these proteins were not significantly altered by
treatment. We then selected three additional proteins that were at least altered in one group.
These include sodium/potassium-transporting ATPase subunit alpha (AT1A3), excitatory amino
acid transporter 2 (EAAT2), and voltage-dependent anion-selective channel protein 1 (VDAC1).
ATPase was selected because significance was present in both treatments and the spectral counts
were high. VDAC1 and EAAT2 were selected for their important functions in our study. The
blots were quantified using the Bio-Rad Image Lab Software, Mac Version 6.1 (SOFT-LIT-1709690—ILMAC-V-6-1) and normalized each replication through the use of β-actin. Following log
transformation of the normalized value, statistical analysis was performed using a one-way
ANOVA using Systat Software (San Jose, CA) to compare the three treatments.

For ATPase, the spectral counts of this protein were significantly decreased with both
CPF (p<0.036) and PF (p<0.048) with a fold decrease of 0.9 with both treatments. The results of
the western blot demonstrated a similar pattern of decrease with both CPF (0.77 fold change) and
PF (0.84 fold change) but the statistical analysis did not indicate a significant difference. Both
the spectral counts and normalized protein percentage and a representative western blot are
presented in Figure 3.11.
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Figure 3.6

The spectral counts from proteomic analysis (A) and the western blot analysis of
normalized protein expression (B) of sodium/potassium-transporting ATPase
subunit alpha (ATPase) in the hippocampus of adolescent rats developmentally
exposed to either corn oil (control), 0.75mg/kg chlorpyrifos, or 0.02mg/kg PF04457845, a specific inhibitory of FAAH. The protein levels were normalized to
the β-actin levels. The western blot depicts ATPase at 112kDa and β-actin at
42kDa. Values are expressed as mean + SEM.

For VDAC1, the spectral counts of this protein were significantly decreased with both
CPF (p<0.041) and PF (p<0.0083) with fold decreases of 0.8 and 0.7, respectively. The results of
the western blot demonstrated a similar pattern of decrease with both CPF (0.73 fold change) and
PF (0.82 fold change) but the statistical analysis did not indicate a significant difference. Both
the average spectral counts and average normalized protein percentage and a representative
western blot are presented in Figure 6.
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Figure 3.7

The spectral counts from proteomic analysis (A) and the western blot analysis of
normalized protein expression (B) of voltage-dependent anion-selective channel
protein 1 (VDAC1) in the hippocampus of adolescent rats developmentally
exposed to either corn oil (control), 0.75mg/kg CPF, or 0.02mg/kg PF-04457845, a
specific inhibitor of FAAH. The protein’s levels were normalized to the β-actin
levels. The western blot depicts VDAC at 33kDa and β-actin at 42kDa. Values are
expressed as mean + SEM.

For EAAT2, the spectral counts of this protein were significantly decreased only with
CPF (p<0.043) with a fold decrease of 08. The results of the western blot demonstrated a similar
pattern of decrease with CPF (0.84 fold change) but not PF. However, but the statistical analysis
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did not indicate a significant difference with the CPF treatment. Both the spectral counts and
normalized protein percentage and a representative western blot are presented in Figure 7.

Figure 3.8

The spectral counts from proteomic analysis (A) and the western blot analysis of
normalized protein expression (B) of excitatory amino acid transporter 2 (EAAT2)
in the hippocampus of adolescent rats developmentally exposed to either corn oil
(control), 0.75mg/kg CPF, or 0.02mg/kg PF-04457845, a specific inhibitor of
FAAH. The protein’s levels were normalized to the β-actin levels. The western
blot depicts EAAT2 at 70kDa and β-actin at 42kDa. Values are expressed as mean
+ SEM.
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CHAPTER IV
DISCUSSION
4.1

Comparison of treated groups regarding altered proteins, GO terms, and canonical
pathways
Comparison of the changes in the adolescent proteome induced by juvenile exposure to

CPF with those induced by juvenile exposure to PF did not yield a large number of similarities.
Only about a third of the altered proteins were similar between the two treatments. However,
there was some agreement in the proteomic analysis for both treatments. In terms of Gene
Ontology, most of the GO terms associated with altered neurological functions that were
identified as significantly altered were similar between the two treatments but there were
differences as well. Similarly, the bioinformatic analysis yielded many of the same altered
canonical pathways and altered diseases and functions but again there were differences. Our
measurements are indicative of persistent changes since the sampling did not occur until over 20
days following cessation of treatment. The discrepancy between the two treatments is probably
the result of CPF having additional targets that were affected which were not affected by
exposure to PF. These were likely responsible for the differences in the effects observed. It’s also
possible that PF has some unknown additional targets as well. However, the similarities
concerning the pathways and functions that were persistently altered between the two treatments
suggest that a significant number of the effects observed following juvenile CPF exposure were
due to the inhibition of FAAH during the exposure period. However, the presence of different
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outcomes of the two treatments suggests that other targets are also involved in the persistent
effects of CPF.
4.2

Identification of altered pathways and their proteins required for proper
hippocampal functioning
The overall hypothesis of this research is juvenile OP exposure to CPF alters synaptic

components/connections of the hippocampus that are important in normal emotional behavior.
The hippocampus is the major structure in the brain regarding learning, memory, and behavior.
All of these are regulated through neural/synaptic connections. Therefore, the slightest
disruption in synaptic connections could have a negative developmental impact, especially
during maturation. For this reason, the most important processes must involve the establishment
and stabilization of synapses for proper cell communication. Through the examination of the
significantly altered proteins and the canonical pathways and functions associated with these
proteins, we have attempted to identify the altered pathways and proteins that are altered by CPF
exposure that we believe are the most important for proper hippocampal function
4.2.1

Glutamate and NMDA receptors
The hippocampus greatly relies on the synaptic connections inside of it to function

correctly. This is especially important when considering how thought and emotion are
transmitted and processed in the brain (Waites et al. 2005), especially since that’s the sole
purpose of synapses—communication. The most important molecule in regulating synapse
formation is glutamate, as it is an agonist of the NMDA receptor, a crucial receptor in the
development of the hippocampus and for the process of synaptogenesis and long-term
potentiation (LTP) (Wenthold et al. 2003). In the absence of glutamate, synaptogenesis or LTP
does not occur causing long-term depression (LTD). This effect will inhibit memory and learning
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from occurring. Moreover, inhibitory neurotransmitters such as glycine and GABA could block
LTP in the hippocampus, therefore elevating the key role the NMDA receptor plays regarding
synaptic plasticity (Wenthold et al. 2003)
4.2.2

Synaptogenesis Signaling Pathway
Perhaps the most important pathway regarding hippocampal development and emotional

behavior that was altered by developmental CPF exposure is the synaptogenesis signaling
pathway, which aids in the formation and development of synapses (Garner et al 2002; Waites et
al. 2005). Since synapses exist to transmit information through the brain, the slightest
disturbance in the formation or structure of the synapse will greatly influence communication.
The initiation of synapse development begins at axonal growth cones/dendritic trees called
axodendritic sites through the presence of cell surface-adhesion molecules (CAMs). CAMs
function in cell-cell recognition, by using inductive signals to trigger the first stages of synapse
formation: the assembly of presynaptic and postsynaptic specializations resulted from neuron
differentiation (Garner et al. 2002; Waites et al. 2005). An example of a CAM that was
significantly altered in our study was Neuroligin 2 (NLGN2), a postsynaptic protein that aids in
synapse specification (inhibitory/excitatory), adhesion, and signaling during synaptogenesis that
trigger formation and of functional presynaptic boutons (Garner et al. 2002; Waites et al. 2005).
It is important to note that while the presence of NLGN2 isn’t necessary for the initial
development of synapses, it has several crucial roles in the stability and maintenance of the
synapse even into adulthood. First, it plays a role in the specificity/function of a synapse, i.e.
excitatory or inhibitory. Whereas over-expression of Neuroligin 1 (NLGN1) increases excitatory
synapses, an over-expression of NLGN2 increases inhibitory synaptic responses (Chubykin et al.
2007) and the balance ultimately determines the E/I ratio (Hines et al. 2008). Secondly, it also
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determines inhibitory synapse morphology. The absence of NLGN2 in knockout mice leads to
altered levels of the protein components of the GABAergic postsynaptic complex and abnormal
inhibitory synaptic transmission indicating NLGN2 is necessary for normal function (Ali et al.,
2020). We observed a significant increase in the protein levels of NLGN2 in the hippocampus of
adolescent rats developmentally exposed to CPF. This increase suggests an imbalance of an E/I
ratio, where GABAergic synapses and information is favored over glutamatergic synapses.
Since the presence of glutamate is necessary for the process of LTP to begin, dictating behavior,
without an adequate concentration of glutamate, synaptogenesis and LTP will be disrupted,
which will inhibit proper development of the hippocampus and other brain areas. Increased
NLGN2 expression results in the promotion of GABA synapses and thereby promotes inhibitory
function (Chubykin et al. 2007; Kohl et al. 2013). Furthermore, the presence of increased
NLGN2 suggests increased GABAergic synapses, thereby creating a disturbance in the E/I ratio
(Sun et al. 2013). This imbalance could play a role in the anxiolytic-like behavior that we have
previously observed (Carr et al, 2020). The increased levels of NLGN2 could be one of many
reasons why the E/I ratio in the hippocampus of developmentally CPF-exposed rats is favoring
inhibitory signals.

Another potential factor in the altered synaptogenesis signaling pathway is the observed
increased levels of Synaptotagmin-2 (Syt2). Synaptotagmins are a family of transmembrane
proteins that sense the presence of Ca2+ and trigger neurotransmitter release from the presynaptic
membrane. Three of these act as fast-release sensors including Syt1, Syt2, and Syt9 with Syt1
and Syt2 being widespread and Syt9 expressed mainly in the limbic system and striatum (Xu et
al., 2007; Kochubey et al., 2016). However, recent immunolabeling work has demonstrated that
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Syt1 is enriched in excitatory terminals whereas Syt2 is selectively expressed in central
inhibitory neurons (Chen et al., 2017). Thus, increased levels of Syt2 suggest the increased levels
of sensors in GABAergic synapses that when activated by increased Ca2+, could enhance the
release of the inhibitory neurotransmitter GABA.

4.2.3

Ephrin family proteins in Ephrin signaling
During the development of dendritic shafts, the cadherins and ephrin family proteins

recruit NMDA receptors on the dendrite shaft surfaces (Garner et al. 2002). There is strong
evidence that the ephrin family proteins are pivotal for dendritic spine development since ephrin
is required for establishing glutamatergic synapses and dendritic spine maturation (Waites et al.
2005). Our bioinformatics analysis indicates that ephrin B signaling, ephrin A signaling, and
ephrin receptor signaling pathways are altered by developmental CPF exposure. The ephrin
family signaling pathways work with the synaptogenesis pathway to further aid in the
development of the brain. This is a pivotal pathway regarding the development of the
hippocampus and nervous system, due to its importance regarding synaptic development and
function (Armstrong 2006; Nolt et al. 2011). This signaling pathway specifically aids in the
initiation of LTP, allowing for proper learning, memory, and behavior. Early in development,
the ephrin receptors are essential for the formation and maintenance of excitatory synaptic
connections (Nolt et al. 2011; Henderson and Dalva, 2018). So, if the function of these pathways
is decreased, it will start a signaling cascade of down-regulated synaptic formation, and LTP
processing, eventually decreasing the function of the hippocampus, and could potentially have
the effect of anxiety we have seen displayed in our treated rats. This disrupted role in the
maintenance of excitatory synaptic connections is also reflected in the fact that our
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bioinformatics analysis also indicated altered glutamatergic receptor signaling. The ephrin B
receptor pathway plays a role in the recruitment of glutamate receptor interacting protein 1
(GRIP1) (Brückner et al., 1999). GRIP1 is a scaffolding protein that regulates the surface
expression and synaptic stabilization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)-type glutamate receptors (AMPARs) (Mao et al., 2012; Mejias et al., 2011). In the
dynamic sense, GRIP1 is important in the trafficking of AMPA receptors in neurological
function and the increased levels of GRIP1 that we observed could disrupt its normal role
inappropriate synaptic plasticity and learning and memory (Tan et al., 2020). Along this same
line of thought, another protein whose levels were increased in our study was the postsynaptic
density protein Rho guanine nucleotide exchange factor Trio (TRIO). TRIO is a substrate of
calcium/calmodulin-dependent protein kinase II (CaMKII) (Herring and Nicoll, 2016) and once
activated is involved in the trafficking of AMPA receptors at established glutamatergic dendrites.
In the hippocampus CA1 excitatory synapses, the activation of TRIO functions to decrease the
endocytosis of AMPA receptors (Ba et al., 2016). As with GRIP1, the increased levels of TRIO
that we observed could indicate disruption of its normal role inappropriate synaptic plasticity and
learning and memory (Herring and Nicoll, 2016).
4.2.4

Proteins that affect glutaminergic functioning
In terms of glutamatergic functioning, we observed increased levels of vesicular

glutamate transporter 2 (SLC17A6 or VGLUT2). VGLUT2 is a common marker for
glutamatergic synapses and is responsible for the import of glutamate into the vesicles in the
presynaptic neuron. This suggests possibly an increase in glutamatergic synapses. We also
observed decreased levels of the excitatory amino acid transporter 2 (SLC1A2 or EAAT2) also
known as the glial high-affinity glutamate transporter (GLT1). EAAT2 is found primarily on
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astrocytes that are adjacent to the synapse. This transporter is crucial for the removal of
glutamate from the synaptic cleft. In fact, it is thought to be responsible for the removal of 90%
of glutamate in most brain areas (Rothstein et al., 1996; Tanaka et al., 1997; Furness et al., Kim
et al., 2011). An increased packaging of glutamate into vesicles combined with a decrease in
uptake of glutamate from the synapse suggests an attempt to enhance excitatory signaling
possibly to overcome the E/I imbalance favoring inhibitory signaling.

Intersectin 2 (ITSN2), whose levels were increased in our study, is a participating protein
in the ephrin signaling pathway and the synaptogenesis pathway. However, it does not
necessarily aid in the initial stages of synapse formation. It is largely involved in the endocytosis
and cell signaling (Herro-Garcia & O’Bryan 2017; Tong et al. 2000) portion of synaptogenesis.
The presence of ITSN2 functions as an inducer of many signaling pathways, such as the
Ras/MAPK pathway. Kumar et al. (2005) reported that chronic suppression of the Ras-MAPK
pathway greatly reduces dendritic trees and complexity, as well as loss of filopodia and dendritic
spines. Functionally, over-expression of ITSN2 regulation/presence, which correlates with an
inhibition of Ras/MAPK signaling, ultimately interferes with cellular communication (Tong et
al. 2000; Kumar et al. 2005). Based on previous studies and our analysis, the process of
synaptogenesis has been disrupted, affecting the morphology, communication, and possibly the
concentrations of glutamate and GABA within the hippocampus, thus, producing the observed
behavioral effects.

It’s important to remember that the hippocampus has a larger concentration of CB1
receptors and our bioinformatics analysis indicates that the endocannabinoid developing neuron
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pathway was predicted to be inhibited. However, the proteins associated with this pathway were
associated with signaling and no direct machinery proteins (i.e., CB1 receptors or synthesis or
degradative enzymes) were altered. The CB1 receptors are known to be expressed at higher
levels in GABAergic neurons than pyramidal cells (Marsicano and Lutz, 1999) and activation of
these receptors inhibits GABA release (Hajos et al., 2000). Thus, if the development of the
endocannabinoid system in the hippocampus has been inhibited, it is possible that the appropriate
signaling necessary to inhibit GABA release has been disrupted, thus, increasing the GABA
concentration.
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CHAPTER V
CONCLUSION
Low dose juvenile chlorpyrifos exposure disrupts the development of the hippocampus,
causing persistent, long-term effects, interfering with proper learning, memory, and behavioral
functions. Our data suggests that alters the establishment, development, and functioning of
synapses by interfering with the synaptogenesis and ephrin signaling pathways. Specifically,
interference with synaptic development and/or stability and maintenance of the synapse by CPF
is suggested by the increased levels of Neuroligin-2, possibly promoting an increase in
GABAergic synapses. The increased levels of Synaptotagmin-2 which is selectively expressed in
GABAergic neurons, also suggests an increase in GABAergic synapses. Similarly, CPF affects
the ephrin signaling pathway by decreasing its activity, thus reducing its ability to aid in the
development of the hippocampus. Since the ephrin receptors are responsible for forming and
maintaining excitatory synapses, decreasing the pathways function of the ephrin receptor
pathway would interfere with the establishment and formation of glutamatergic synapses. In
addition, the altered levels of proteins associated with AMPA receptor trafficking, such as GRIP
and TRIO, suggest that glutamatergic synaptic signaling is also disrupted.
Together, these effects on GABAergic and glutamatergic signaling suggest that there is a
disruption of the E/I ratio. Our data suggest that the disruption involves much larger GABA
activity than glutamatergic activity. This increase in inhibition could greatly reduce long-term
potentiation, prohibit proper synapse formation, and disrupt the proper functioning of the
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hippocampus and other brain areas. Therefore, we can conclude that the process of
synaptogenesis has been disrupted, affecting the morphology, communication, and the amount of
glutamate and GABA signaling within the hippocampus. These changes produced the anxiolytic
behavioral effects that have been observed. Moreover, both of our treatment groups regarding
pathways and functions showed persistent alterations between the two groups, indicating that
these effects are a result of FAAH inhibition following juvenile CPF exposure.
Our data provides more insight into how the mechanism of toxicity affects juveniles
through low-dose CPF exposure. Low-dose CPF inhibits FAAH, causing an accumulation of
anandamide. Anandamide accumulation will cause an overstimulation of the endocannabinoid
system which affects the development of the nervous system leading to an abnormal E/I ratio of
signaling.
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